RAD Completes Meeting with US FDA for Development of RAD101

Oct 4, 2026 at 5:40 PM EDT · Issued by Radiopharm Theranostics Limited via ASX

Filed with ASX · Oct 4, 2026 at 5:40 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/rad-completes-meeting-with-us-fda-for-development-of-rad101

Release

ASX ANNOUNCEMENT October 5, 2026 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101...

Radiopharm Theranostics Limited on 6ix

Story so far

RAD to meet with US FDA to align on RAD 101 Phase 3 TrialAug 16, 2026
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)Jul 28, 2025
RAD receives IND approval from US FDA for Betabart (RV-01)Jul 28, 2025

Earlier from Radiopharm Theranostics

Notification of cessation of securities - RADOct 1
Change of Director's Interest Notice (RC)Oct 1
Appendix 4G and Corporate Governance StatementSep 30
Annual Report and Form 20-FSep 30
Change of Director's Interest Notices x 4Sep 22

Later from Radiopharm Theranostics

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101Oct 5
Non-Compliance with Listing Rule 10.11Oct 11
Notification regarding unquoted securities - RADOct 20
Radiopharm receives $8M advance on FY26 R&D tax incentiveOct 26
Notice of Annual General Meeting/Proxy FormOct 26

All Radiopharm Theranostics news releases

Follow Radiopharm Theranostics into a list and get an email when it puts out news.

Follow Radiopharm Theranostics